Longitudinal Imaging Biomarkers of Disease Progression in DLB (U01)

Brad Boeve
PI:
Brad Boeve
Mayo Clinic (Rochester, Minnesota)
Kejal Kantarci
PI:
Kejal Kantarci
Mayo Clinic (Rochester, Minnesota)

Summary

​​​​​Dementia with Lewy bodies (DLB) is a disorder in which patients develop a combination of Alzheimer’s disease and Parkinson’s disease-like symptoms and brain pathologies.   This project will build on what is known about neuroimaging characteristics of Alzheimer’s and Parkinson’s disease to identify neuroimaging features that may be specific for DLB.  Identifying brain imaging markers combined with genetic and clinical profiles may help diagnose DLB, track disease progression and response to new therapies.

Abstract

​​​​Dementia with Lewy bodies (DLB) is a clinical syndrome characterized by the presence of Lewy body disease (LBD), but additional Alzheimer’s disease (AD)-related pathology is also common in patients with DLB. Although the impact of each of these two pathologies on the clinical disease progression is not fully understood, many DLB patients may benefit from treatments that target both AD and LBD-related pathological processes. To prepare for these clinical trials in DLB, we need robust and reliable biomarkers that can track disease progression, particularly the progression of both LBD- and AD-related pathologies. We propose multi-modal imaging biomarkers of pathological processes commonly present in patients with DLB to detect disease progression. We propose to establish a longitudinal cohort of patients with DLB and acquire clinical and multi-modal imaging biomarker data to model the longitudinal imaging biomarker changes with respect to clinical disease progression in DLB. In Aim 1, we propose to determine whether LBD-related dopaminergic loss on SPECT, and AD pathophysiology measured with higher amyloid-β deposition on PET and AD-signature atrophy on MRI is associated with the rate of clinical disease progression, cognitive decline and survival in DLB; In Aim 2, we will determine whether these longitudinal changes in imaging biomarkers and clinical outcomes, and their associations are modified by genetic, sex based, and cerebrovascular disease-related features. In Aim 3, we will determine the pattern of a tau ligand AV-1451 uptake in DLB compared to controls and its relationship to the rate of change in imaging biomarkers and clinical disease progression. Finally, we will determine the pathologic basis of the biomarker changes in DLB in autopsied patients, which is the gold standard for validating imaging biomarkers in Aim 4. In addition to these aims that focus on hypothesis testing, we will collect whole blood, plasma, serum, CSF, and urine samples, clinical and harmonized neuroimaging data longitudinally; DNA and peripheral blood mononuclear cells from a prospective cohort of DLB patients.

Goals

Goals of the Project

  • Enroll and follow 90 patients with Dementia with Lewy Bodies (DLB) over time with cognitive, motor, behavioral and imaging measures. Imaging measures include:
    • AV-1451 PET at baseline (tau pathology)
    • DaTscan SPECT annually (Dopamine transporter)
    • PiB or Florbetapir PET annually (amyloid pathology)
    • Structural MRI annually (ADNI-3 protocol)
  • Perform brain autopsies on all deceased participants who consent to brain donation.
  • Enrollment Goals
  • 90 Dementia with Lewy Bodies (DLB) patients

Please contact:

Neill Graff-Radford
Site Investigator
Mayo Clinic (Jacksonville, Florida)

Participate

To participate in this study, please contact one of the following:

Please contact:

Heather Cissel
Clinical Coordinator
Mayo Clinic (Florida)
Mayo Clinic
Clinical Coordinator
Mayo Clinic (Minnesota - Primary)